Literature DB >> 16033920

Enhanced tubuloglomerular feedback in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension.

Kenneth D Mitchell1, John J Mullins.   

Abstract

The present study was performed to evaluate tubuloglomerular feedback responses in transgenic rats [TGR(Cypa1a1Ren2)] with inducible malignant hypertension and to determine the degree to which feedback responsiveness is modulated by ANG II in these rats. Male Cyp1a1-Ren2 rats were fed a normal diet containing the aryl hydrocarbon indole-3-carbinol (I3C; 0.3%), for 5-6 days to stimulate expression of the Cyp1a1-Ren2 transgene and, thereby, to induce malignant hypertension. Stop-flow pressure (SFP) feedback responses to a late proximal perfusion rate of 40 nl/min were assessed in pentobarbital sodium-anesthetized rats during control conditions and after administration of the AT(1) receptor antagonist candesartan (0.1 mg/kg iv). Rats induced with I3C (n = 6) exhibited elevated mean arterial pressure and increased maximal SFP feedback responses compared with noninduced rats (n = 4; 163 +/- 4 vs. 130 +/- 2 mmHg, P < 0.01 and 16.3 +/- 1.4 vs. 11.7 +/- 0.5 mmHg, P < 0.05, respectively). Systemic candesartan decreased arterial pressure (to 98 +/- 7 and to 101 +/- 5 mmHg, respectively, P < 0.001) and attenuated SFP feedback responses (to 2.0 +/- 0.4 and to 3.3 +/- 0.9 mmHg, respectively, P < 0.01) in both hypertensive and normotensive rats. In additional experiments, peritubular capillary infusion of 10(-3) M candesartan did not alter arterial pressure but attenuated feedback responses in both hypertensive (19.3 +/- 1.4 to 8.8 +/- 0.9 mmHg, P < 0.01, n = 9) and normotensive Cyp1a1-Ren2 rats (9.0 +/- 0.8 to 4.7 +/- 0.6 mmHg, P < 0.01, n = 7). The present findings indicate that Cyp1a1-Ren2 rats with ANG II-dependent malignant hypertension exhibit augmented tubuloglomerular feedback responses. The data also show that AT(1) receptor activation by ANG II contributes to the enhanced feedback responsiveness in Cyp1a1-Ren2 rats with malignant hypertension.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16033920     DOI: 10.1152/ajprenal.00461.2004

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  12 in total

1.  Renal mechanisms contributing to the antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats with inducible hypertension.

Authors:  Zuzana Honetschlägerová; Zuzana Husková; Zdeňka Vaňourková; Alexandra Sporková; Herbert J Kramer; Sung Hee Hwang; Hsing-Ju Tsai; Bruce D Hammock; John D Imig; Luděk Červenka; Libor Kopkan
Journal:  J Physiol       Date:  2011-01-01       Impact factor: 5.182

2.  Chronic direct renin inhibition with aliskiren prevents the development of hypertension in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent hypertension.

Authors:  Lily Huang; Catherine G Howard; Kenneth D Mitchell
Journal:  Am J Med Sci       Date:  2012-10       Impact factor: 2.378

3.  Transient induction of ANG II-dependent malignant hypertension causes sustained elevation of blood pressure and augmentation of the pressor response to ANG II in CYP1A1-REN2 transgenic rats.

Authors:  Catherine G Howard; John J Mullins; Kenneth D Mitchell
Journal:  Am J Med Sci       Date:  2010-06       Impact factor: 2.378

4.  Direct renin inhibition with aliskiren normalizes blood pressure in Cyp1a1-Ren2 transgenic rats with inducible angiotensin ii-dependent malignant hypertension.

Authors:  Catherine G Howard; John J Mullins; Kenneth D Mitchell
Journal:  Am J Med Sci       Date:  2011-05       Impact factor: 2.378

5.  Imatinib ameliorates renal morphological changes in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension.

Authors:  Miguel L Graciano; Kenneth D Mitchell
Journal:  Am J Physiol Renal Physiol       Date:  2011-10-05

6.  Renal functional responses to selective intrarenal renin inhibition in Cyp1a1-Ren2 transgenic rats with ANG II-dependent malignant hypertension.

Authors:  Catherine G Howard; Kenneth D Mitchell
Journal:  Am J Physiol Renal Physiol       Date:  2011-10-12

7.  Enhancement of renin and prorenin receptor in collecting duct of Cyp1a1-Ren2 rats may contribute to development and progression of malignant hypertension.

Authors:  Minolfa C Prieto; Dustyn E Williams; Liu Liu; Kimberly L Kavanagh; John J Mullins; Kenneth D Mitchell
Journal:  Am J Physiol Renal Physiol       Date:  2010-11-10

8.  Angiotensin-converting enzyme is a modifier of hypertensive end organ damage.

Authors:  Xiaojun Liu; Christopher O C Bellamy; Matthew A Bailey; Linda J Mullins; Donald R Dunbar; Christopher J Kenyon; Gillian Brooker; Surasak Kantachuvesiri; Klio Maratou; Ali Ashek; Allan F Clark; Stewart Fleming; John J Mullins
Journal:  J Biol Chem       Date:  2009-03-23       Impact factor: 5.157

9.  Breeding Characteristics and Dose-dependent Blood Pressure Responses of Transgenic Cyp1a1-Ren2 Rats.

Authors:  Catherine J Leader; Barbara J Clark; Amber R Hannah; Ivan A Sammut; Gerard T Wilkins; Robert J Walker
Journal:  Comp Med       Date:  2018-09-05       Impact factor: 0.982

10.  Lack of cardiac fibrosis in a new model of high prorenin hyperaldosteronism.

Authors:  Jörg Peters; Torsten Schlüter; Thomas Riegel; Barbara S Peters; Andreas Beineke; Ulrike Maschke; Norbert Hosten; John J Mullins; Rainer Rettig
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-09-11       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.